VAM
FRTX

Visium Asset Management’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Visium Asset Management’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-159
Closed -$590K – 1055
2013
Q4 		$590K Buy
+159
New +$602K 0.01% 556

Other funds holding FRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Visium Asset Management's FRTX Position: Q1 2014 in Review

Visium Asset Management sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q1 2014, closing a stake of 159 shares — an estimated $590K sold.

Visium Asset Management first reported a position in FRTX in Q4 2013 and held it in 1 quarter. The position peaked at $590K in Q4 2013. 78 funds tracked by Wall St. Rank hold FRTX as of Q1 2014.

  • Visium Asset Management reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q1 2014 after selling out during the quarter.
  • Visium Asset Management sold 159 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q1 2014, an estimated $590K.
  • Visium Asset Management first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q4 2013 and held it in 1 quarter.
  • Visium Asset Management's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $590K in Q4 2013.
  • 78 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q1 2014.

Based on Visium Asset Management's 13F filing for Q1 2014, filed 15 May 2014.